Photo supplied by CDP Venture Capital.
€2m · Other round · Healthtech · Milan, Italy
Milan-based Holifya, a digital clinic for pharmacological treatment of obesity and metabolic syndrome, has closed a €2m financing round. The round was led by Next Age, the Silver Economy programme created by CDP Venture Capital and AC75, with Growth Engine, Doorway, 20Fund and Zooga VC also participating. Holifya says the capital will expand its clinical, technology and data teams, develop proprietary AI models and grow distribution partnerships across Italy.
The headline amount combines €1.6m of equity with €0.4m of debt capital and grants. That mix matters: the equity supports company-building while the debt and non-dilutive component sit inside the same announced financing package.
Beyond the prescription
Holifya sells a subscription-based care pathway rather than a one-off consultation. Its Patient Support Program brings specialist doctors, nutritionists, nurses and coaches into a single service for patients taking GLP-1/GIP obesity medicines. According to the company, its platform combines as many as 3,000 genetic, blood and medical-history biomarkers with behavioural and clinical data gathered during treatment.
The AI layer is designed to alert the treating doctor to dropout risk or possible adverse effects, suggest when dosage may need review and automate follow-up escalation. Clinical decisions remain with the physician. That human-in-the-loop boundary is important commercially as well as clinically: Holifya is selling continuity and supervision around the medicine, not an autonomous prescription engine.
Holifya launched in 2023 and says it has treated more than 3,000 people. Founder and CEO Alessandra Cestaro told Forbes Italia that the clinic manages more than 800 active patients a month. The company also reports six-month weight loss of 14–17% and adherence up to three times market benchmarks; those figures are company-reported operating data rather than independently validated clinical-trial results.
Distribution is the next test
The funding will support both direct-to-consumer growth and partnerships with pharmaceutical companies, clinics and insurers; Forbes also reports pharmacies as a target channel. Those routes could lower customer-acquisition friction and make Holifya's programme part of an existing treatment journey. They also raise the execution bar: partners will need evidence that the service improves adherence and outcomes without adding complexity for clinicians.
Holifya aims to grow beyond 60 employees by the end of 2026, prioritising its clinical network alongside tech, data and growth hires. The round therefore finances two linked assets: the software that identifies intervention points and the care team that acts on them. Scaling one without the other would weaken the model; the test is whether Holifya can standardise that combination while preserving medical oversight.
Sources checked:
CDP Venture Capital · Forbes Italia · Holifya · Tech.eu Funding Explorer
